Table of Contents
The initiative focuses on point-of-care testing in emergency departments and nontraditional settings to address rising congenital syphilis rates. The U.S. Department of Health and Human Services announced a $4 million initiative to expand access to rapid, point-of-care syphilis testing, launching the HHS rapid syphilis testing initiative to reach women where they actually receive care.
The Scale of the Problem Behind the HHS Rapid Syphilis Testing Initiative
The program focuses on reaching women in emergency departments and other nontraditional healthcare settings to prevent the transmission of the infection to infants. Congenital syphilis cases have risen for 12 consecutive years, with nearly 4,000 cases reported in 2024, representing a nearly 700% increase over the past decade. In 2023, congenital syphilis contributed to 279 stillbirths and infant deaths.
How Preventable These Cases Are
HHS estimates that 83% of congenital syphilis cases in 2023 could have been prevented with timely testing and treatment. “Congenital syphilis is preventable, yet too many mothers and babies are still suffering its devastating consequences,” HHS Secretary Robert F. Kennedy Jr. said in a release. “HHS is putting rapid tests where women receive care so we can detect infections earlier, treat them faster, and protect more babies.”
Why Point-of-Care Testing Is Central to the HHS Rapid Syphilis Testing Initiative
Point-of-care syphilis tests provide rapid results, allowing healthcare providers to begin treatment immediately rather than waiting for traditional laboratory testing. This speed is critical for closing gaps in care, particularly for women who do not regularly visit traditional clinical settings.
The Testing Gap This Initiative Aims to Close
According to HHS data, more than 40% of pregnant women who delivered a baby with congenital syphilis in 2023 did not receive a syphilis test in time to receive adequate treatment before delivery. Syphilis during pregnancy can lead to miscarriage, stillbirth, infant death, and lifelong medical complications.
How the HHS Rapid Syphilis Testing Initiative Is Funded and Structured
Through this initiative, HHS is directing approximately $3.25 million in supplemental awards to the CDC Division of STD Prevention. The funding will support recipients of the CDC Strengthening STD Prevention and Control for Health Departments cooperative agreement to expand access to point-of-care testing and link patients to care from August 2026 through February 2027.
How Jurisdictions Were Selected
The awarded jurisdictions were identified based on a high burden of syphilis and congenital syphilis. Remaining funding will support national partners providing technical assistance and implementation support.
Which Nontraditional Settings the HHS Rapid Syphilis Testing Initiative Targets
The initiative aims to promote screening and treatment beyond traditional healthcare environments by strengthening partnerships across public health programs. Targeted settings include emergency departments, maternal and child health programs, correctional intake settings, and substance use treatment programs.
Why These Specific Settings Were Chosen
By strengthening collaboration across emergency departments, maternal and child health programs, correctional intake, and substance use treatment settings, this initiative reflects a recognition that many women affected by rising congenital syphilis rates may not have regular contact with traditional prenatal or primary care, making these alternative touchpoints critical for earlier diagnosis.
What This HHS Rapid Syphilis Testing Initiative Means Going Forward
With funding running from August 2026 through February 2027, this initiative gives CDC’s STD Prevention Division recipients a defined window to demonstrate whether expanded point-of-care testing in these nontraditional settings can meaningfully close the diagnosis gap that HHS says left 83% of 2023’s congenital syphilis cases preventable. Given the targeted jurisdictions were selected specifically for their high syphilis and congenital syphilis burden, the initiative’s impact may be most visible in these highest-need areas before any broader national expansion is considered.
What to Watch Going Forward
As this initiative moves from announcement to implementation over the coming months, public health officials and clinical laboratories will likely watch closely for early indicators of increased testing rates and diagnosis in emergency departments and the other nontraditional settings targeted. Given the persistent, decade-long rise in congenital syphilis cases this HHS rapid syphilis testing initiative aims to reverse, the program’s ultimate success will likely be measured by whether congenital syphilis case counts and associated stillbirths and infant deaths begin declining in the jurisdictions receiving this targeted funding.
For more healthcare industry updates, insights and news, visit DistilINFO. Click here to subscribe to stay informed.
